Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
10,125 total articles
Artiva Biotherapeutics announced its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. The company plans to initiate a Phase 3 registrational trial of its lead cell therapy candidate, AlloNK, for refractory rheumatoid arthritis in 2026. AlloNK is being evaluated in multiple ongoing clinical trials ta…
Akebia Therapeutics announced that its Chief Financial and Business Officer and Chief Commercial Officer will present at the 2026 Jefferies Global Healthcare Conference. The company focuses on biopharmaceutical treatments for kidney disease and is headquartered in Cambridge, Massachusetts.
Medicus Pharma Ltd. announced a $22 million non-dilutive structured financing facility that strengthens its cash position to nearly $30 million, providing over 24 months of operating cash runway. This financing, including secured promissory notes, is intended to support the advancement of clinical programs, strategic initiatives, and repay existing…
authID and Rubidex have formed a strategic OEM partnership integrating authID’s biometric identity verification with Rubidex’s operational intelligence platform. This collaboration aims to eliminate reliance on passwords by enabling secure, continuous identity verification across distributed AI-driven and operational environments, enhancing fraud p…
Vera Bradley, Inc. announced it will report its first quarter fiscal year 2027 financial results on June 11, 2026, followed by a conference call to discuss the performance. The company operates through two segments—Direct sales via stores and online platforms, and Indirect sales through specialty retailers and licensing agreements.
Prime Medicine announced CEO Allan Reine's participation in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026. The presentation will focus on the company's proprietary Prime Editing platform designed to create one-time curative genetic therapies targeting liver, lung, immunology, and oncology diseases. Prime Medicine aim…
Rhythm Pharmaceuticals announced the publication of a new consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS) in the American Journal of Medical Genetics. This updated clinical tool aims to streamline and speed up diagnosis of BBS by providing clearer criteria and integrating advances in understanding the disease and genetic testi…
Currenc Group Inc., a Nasdaq-listed fintech and AI infrastructure company, appointed Kelly Leung as Venture Partner to advance its strategic growth in Web3, AI infrastructure, and digital asset markets. Leung's extensive global experience in strategic alliances and Web3 ecosystem development is expected to strengthen Currenc's partnerships and acce…
Tyson Foods, a leading protein company listed on the NYSE under ticker TSN, announced the appointment of Jeff Schomburger as its new President and CEO effective October 4, 2026. Schomburger, previously a Tyson Foods board member and former Procter & Gamble executive, will succeed Donnie King, who retires after a 43-year career with the company. The…
The Metals Company Inc. announced that NOAA has formally certified its USA B exploration license application for polymetallic nodule mining on approximately 122,000 km2 of U.S. seafloor. The certification marks a significant regulatory milestone, allowing NOAA to begin preparation of an Environmental Impact Statement. This progress supports the com…
Design Therapeutics, a clinical-stage biotechnology firm focusing on gene-targeted therapies for degenerative genetic diseases, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. The company’s management will discuss their ongoing clinical programs and pipeline developments.
Metagenomi Therapeutics, an in vivo genome editing company focused on curative genetic medicines, will present at the Jefferies Global Healthcare Conference on June 4, 2026. The presentation will highlight their proprietary CRISPR-based technologies and lead program MGX-001 for hemophilia A, along with other pipeline developments targeting cardiome…
Oruka Therapeutics, a clinical-stage biotech company focused on novel biologics for chronic skin diseases like plaque psoriasis, announced its upcoming presentation at the 2026 Jefferies Global Healthcare Conference in New York. The event will provide a platform to share progress and innovations with investors and the healthcare community.
Diginex Limited's subsidiary Matter has tripled carbon data extraction automation from 25% to 80% using advanced AI and multi-stage quality controls. This technological breakthrough enables faster and more accurate carbon and sustainability data delivery from over 1,000 companies, providing institutional investors managing $20 trillion in assets wi…
Byrna Technologies Inc. announced a new media partnership with Fox Sports through iHeartMedia to launch a campaign targeting a broad sports audience with its less-lethal personal security products. This initiative is part of Byrna's strategic marketing evolution to broaden consumer outreach and enhance brand awareness through multi-platform adverti…
AgEagle Aerial Systems, operating as EagleNXT and listed on the NYSE under UAVS, announced the opening of a new global headquarters and state-of-the-art manufacturing and innovation facility in Allen, Texas. This U.S.-based center consolidates assembly, R&D, and administrative functions, focusing on advanced drone and sensor production including ND…
CECO Environmental Corp. and Thermon Group Holdings announced that their stockholders have overwhelmingly approved the strategic combination between the two companies, with over 99% votes in favor at their respective meetings. The transaction, expected to close around June 1, 2026, will combine CECO's environmental and industrial process solutions …
CRISPR Therapeutics AG, a leader in gene editing therapies and pioneer in CRISPR/Cas9 technology, announced its senior management will participate in key investor conferences in June 2026, including Jefferies, William Blair, and Goldman Sachs events. The company highlighted its recent FDA approval of CASGEVY®, the first CRISPR-based therapy for sic…
Eupraxia Pharmaceuticals, a clinical-stage biotech company specializing in its Diffusphere™ technology for targeted and controlled drug delivery, announced its management team's upcoming presentation at the Jefferies Global Healthcare Conference. The company is advancing clinical trials for its product candidates EP-104GI for EoE and EP-104IAR for …
Aveanna Healthcare Holdings Inc. announced a successful repricing of its first lien and revolving credit facilities, resulting in a 50 basis point reduction in interest margins, with potential for an additional 25 basis point reduction upon credit rating upgrades. This refinancing move strengthens Aveanna's balance sheet and supports ongoing strate…
CPS Technologies Corp. has priced a registered direct offering of 1.2 million common shares at $8.00 per share, raising approximately $9.6 million before expenses. The proceeds will be used for general corporate purposes including working capital, capital expenditures, and commercialization of developing technologies. The offering is conducted unde…
BioCardia, Inc. announced that Japan's PMDA has issued a Consultation Record supporting the regulatory submission of CardiAMP Cell Therapy for ischemic heart failure with reduced ejection fraction (HFrEF). This follows successful clinical trials and confirms alignment on remaining questions ahead of submission. BioCardia plans to submit its applica…
PROCEPT BioRobotics announced the completion of enrollment for the randomized WATER IV study comparing Aquablation therapy to radical prostatectomy, and obtained FDA IDE approval for a second randomized study evaluating Aquablation therapy versus active surveillance in prostate cancer patients. Both studies aim to assess long-term disease control a…
Immutep Limited announced positive clinical data from an analysis of five trials showing that eftilagimod alfa (efti), an antigen-presenting cell activator, combined with standard-of-care therapies, significantly improves overall survival in late-stage cancer patients. The data indicate immune activation correlates with clinical benefit across vari…
Monster Beverage Corporation announced that its senior management team will participate in a live fireside chat at the dbAccess Global Consumer Conference on June 4, 2026, detailing ongoing developments in its energy drink and alcoholic beverage segments.
